Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Bucladesine, Pentoxifylline, and H-89 As Cyclic Adenosine Monophosphate Analog, Phosphodiesterase, and Protein Kinase a Inhibitor on Acute Pain Publisher Pubmed



Salehi F1 ; Hosseinizare MS1, 2 ; Aghajani H3 ; Seyedi SY1 ; Hosseinizare MS1, 2 ; Sharifzadeh M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacology and Toxicology, Pharmaceutical Science Research Center, Tehran University of Medical Science, PO Box 14155-6451, Tehran, Iran
  2. 2. Department of Biology and Biochemistry, University of Houston, Houston, 77204, TX, United States
  3. 3. Department of Biomedical Engineering, University of Houston, Houston, 77204, TX, United States

Source: Fundamental and Clinical Pharmacology Published:2017


Abstract

The aim of this study was to determine the effects of cyclic adenosine monophosphate (cAMP) and its dependent pathway on thermal nociception in a mouse model of acute pain. Here, we studied the effect of H-89 (protein kinase A inhibitor), bucladesine (Db-cAMP) (membrane-permeable analog of cAMP), and pentoxifylline (PTX; nonspecific phosphodiesterase (PDE) inhibitor) on pain sensation. Different doses of H-89 (0.05, 0.1, and 0.5 mg/100 g), PTX (5, 10, and 20 mg/100 g), and Db-cAMP (50, 100, and 300 nm/mouse) were administered intraperitoneally (I.p.) 15 min before a tail-flick test. In combination groups, we injected the first and the second compounds 30 and 15 min before the tail-flick test, respectively. I.p. administration of H-89 and PTX significantly decreased the thermal-induced pain sensation in their low applied doses. Db-cAMP, however, decreased the pain sensation in a dose-dependent manner. The highest applied dose of H-89 (0.5 mg/100 g) attenuated the antinociceptive effect of Db-cAMP in doses of 50 and 100 nm/mouse. Surprisingly, Db-cAMP decreased the antinociceptive effect of the lowest dose of H-89 (0.05 mg/100 g). All applied doses of PTX reduced the effect of 0.05 mg/100 g H-89 on pain sensation; however, the highest dose of H-89 compromised the antinociceptive effect of 20 mg/100 g dose of PTX. Co-administration of Db-cAMP and PTX increased the antinociceptive effect of each compound on thermal-induced pain. In conclusion, PTX, H-89, and Db-cAMP affect the thermal-induced pain by probably interacting with intracellular cAMP and cGMP signaling pathways and cyclic nucleotide-dependent protein kinases. © 2017 Societe Francaise de Pharmacologie et de Therapeutique
Experts (# of related papers)